ICMJE DISCLOSURE FORM

Date:O	October, 27, 2023	
Your Name:_	Tsukasa Ishiwata	
Manuscript 1	Title: Endoscopic Treatment for Lung Cancer	
Manuscript r	number (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present	x_None	planning of the work
	manuscript (e.g., funding, provision of study materials,		
	medical writing, article		
	processing charges, etc.) No time limit for this item.		
	No time mine for this term.		
		Time frame: past	36 months
2	Grants or contracts from	xNone	
	any entity (if not indicated in item #1 above).		
3	Royalties or licenses	x None	
	No yanties of meetises		
4	Consulting fees	xNone	

5	Payment or honoraria for	xNone		
	lectures, presentations,			
	speakers bureaus, manuscript writing or			
	educational events			
6	Payment for expert	x_None		
	testimony			
7	Support for attending meetings and/or travel	x_None		
8	Patents planned, issued or	xNone		
	pending			
_	Double in the control of the control	v Nana		
9	Participation on a Data Safety Monitoring Board or	xNone		
	Advisory Board			
10	Leadership or fiduciary role	x None		
	in other board, society,			
	committee or advocacy			
	group, paid or unpaid			
11	Stock or stock options	xNone		_
12	Receipt of equipment,	x None		_
	materials, drugs, medical			_
	writing, gifts or other			
	services			_
13	Other financial or non-	x_None		
	financial interests			_
Plea	Please summarize the above conflict of interest in the following box:			
	Dr. Ishiwata has nothing to disclose.			

Please place an "X" next to the following statement to indicate your agreement:

_X__ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date:	_October, 27, 2023	
Your Name	e:Kazuhiro Yasufuku	
Manuscrip	ot Title: Endoscopic Treatment for Lung Cancer	
Manuscrip	ot number (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
1	All conservation the conservation	Time frame: Since the initia	planning of the work	
1	All support for the present	xNone		
	manuscript (e.g., funding, provision of study materials,			
	medical writing, article			
	processing charges, etc.)			
	No time limit for this item.			
	Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated	Olympus Corp.	To my institution	
		Johnson and Johnson	To my institution	
	in item #1 above).	ODS Medical Inc.	To my institution	
3	Royalties or licenses	xNone		
4	Consulting fees	Olympus America Inc.	To my institution	
		Medtronic	To my institution	

		Johnson and Johnson	To my institution
		Astra Zeneca	To my institution
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	_xNone	
6	Payment for expert testimony	xNone	
7	Support for attending meetings and/or travel	_x_None	
8	Patents planned, issued or pending	xNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	x_None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	x_None	
11	Stock or stock options	xNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	xNone	
13	Other financial or non- financial interests	OKF Technology Olympus America Inc. Medtronic	Research collaboration advisory board advisory board
		Johnson and Johnson	advisory board

Please summarize the above conflict of interest in the following box:

Dr. Yasufuku has industry-sponsored grants from Olympus Corp., Johnson and Johnson, and ODS Medical Inc., serves as a consultant for Olympus America Inc., Medtronic, Johnson and Johnson, and Astra Zeneca, collaborates on research with OKF Technology, and sits on the advisory board of Olympus America Inc., Medtronic, and Johnson and Johnson.

Please place an "X" next to the following statement to indicate your agreement:		
_X I certify that I have answered every question and have not altered the wording of any of the questions on thi form.		